Mohammed Abouelsoud - CEO, U: The Mind Company - Rebooting The Brain: Precision Noninvasive Neuromodulation

Mohammed “Mo” Abouelsoud is a neuroscientist-entrepreneur whose career sits at the intersection of brain science, noninvasive neuromodulation, and precision healthcare. He is the CEO of U: The Mind Company ( https://uthemind.company ), where he leads the development of precision, noninvasive neuromodulation technologies aimed at restoring dysfunctional brain networks in Parkinson’s disease and other neurological disorders. 

Mo’s journey into neuroscience began long before the boardroom—rooted instead in hands-on clinical exposure and early immersion in brain imaging and data science. While training at The Ohio State University Wexner Medical Center, he worked in a neuromodulation data analysis lab, learning to map structural and functional brain connectivity using DTI and fMRI, and gaining fluency in tools such as MATLAB and FSL. This early exposure shaped his enduring interest in the brain not as isolated regions, but as dynamic, networked systems that can be measured, modeled, and—critically—modulated.

At OSU, Mo further expanded his technical foundation through research spanning nanotechnology, fluorescence imaging, and signal measurement, synthesizing DNA-gold nanoparticle conjugates for precision sensing. Across these experiences, a unifying question emerged: how can we quantify brain function objectively, and how can we intervene noninvasively to restore lost connectivity?

That question became the backbone of his entrepreneurial work. Prior to founding U: The Mind Company, Mo co-founded Tremo, a quantitative tracking platform designed to objectively measure motor symptoms and treatment response in neurological disease—an early step toward personalized, data-driven neurology.

At U: The Mind Company, Mo now leads a multidisciplinary effort combining transcranial electrical stimulation (tES), neuroimaging, advanced signal analytics, and AI-driven interpretation within the company’s Compressive Healthcare Intelligence Platform (CHIP). His work has helped demonstrate that targeted frontal lobe stimulation can significantly enhance functional connectivity in Alzheimer’s disease networks, with observed increases in local and interhemispheric coherence that suggest meaningful neuroplastic re-engagement of impaired circuits. In Parkinson’s disease, his team has shown measurable reductions in tremor and dyskinesia using objective video analysis and motor tracking—bringing rigor and quantification to outcomes that have traditionally been subjective.

Threaded throughout Mo’s neuroscience journey is an unusually holistic worldview. Before entering research and medicine, he spent years working in permaculture and regenerative farming, an experience that deeply influenced his systems-level thinking. Just as ecosystems thrive through balance, feedback, and interdependence, Mo approaches the brain as a living network—one that can be guided back toward health through precise, adaptive intervention rather than blunt force. 

Today, Mo Abouelsoud is driven by a singular mission: to translate neuroscience into scalable, noninvasive technologies that restore brain function, dignity, and agency to patients, while redefining how neurological disease is measured, treated, and understood.

Important Episode Link - Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms -

https://clinicaltrials.gov/study/NCT07182058 

#MohammedAbouelsoud #UTheMindCompany #Noninvasive #Neurotechnology #Neuromodulation #Electroceuticals #TranscranialElectricalStimulation #TranscranialDirectCurrentStimulation #TranscranialAlternatingCurrentStimulation #AlzheimersDisease #ParkinsonsDisease #PsychiatricDisorders #DigitalTwinBrain #STEM #Innovation #Science #Technology #Re